Ranbaxy to market French firm's drug

MUMBAI: India's leading drug maker, Ranbaxy Laboratories, said on Monday it would market a combination of drugs produced by France's Ethypharm S.A.   

It will sell a combination of Fenofibrate, prescribed to lower triglycerides, and Atorvastatin, which lowers cholesterol, the company said in a statement.   

The drug will be manufactured by Ethypharm near Mumbai, and branded as Storfib, it said.   

"The launch of Storfib ... would further augment our leadership position in the cardio-vascular market," Sanjeev I Dani, Ranbaxy's regional director for India and the Middle East, said.   

In May, Ranbaxy entered into a similar agreement to market Ethypharm's painkiller tablet, Tramadol, in India.   

Ranbaxy's shares closed 0.85 per cent higher at 417.55 rupees in a firm Mumbai market.